āshibio Presents Biomarker Data Supporting Vantictumab Development for ADO2 and a Prevalence Estimate of CLCN7 — Related ADO2 of 1—4 per 20,000 Individuals
For best results when printing this announcement, please click on link below: āshibio Presents Biomarker Data Supporting Vantictumab Development for ADO2 and a Prevalence Estimate of CLCN7-Related ADO2 of 1—4 per 20,000 Individuals — Biomarker data demonstrate osteoclast activation at low doses of vantictumab without i